GE Healthcare presents data on PET imaging agent

04/11/2010 | Medical News Today

GE Healthcare has undertaken a Phase II trial on PET imaging agent flutemetamol that examined the efficacy of the agent in identifying the patients with clinically probable Alzheimer's disease. Results were to be presented at a conference in Canada. The company also has initiated the agent's Phase III trial program.

View Full Article in:

Medical News Today

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Principal Engineer - Service (US/MI/00/0043/SL) - 14000009CP
Chicago, IL
Senior Manager, Compliance
Fremont, CA
Manager, Business Conduct
Foster City, CA
Product Patent Attorney
Foster City, CA
Employment Counsel
Foster City, CA